Methyldopa hydrate (MK-351 hydrate) is a DOPA decarboxylase inhibitor and indirect alpha2-adrenergic receptor agonist used to treat hypertension. It inhibits the sympathetic nervous system, decreases production of dopamine, norepinephrine, and epinephrine, and exhibits NO-dependent sedative activity.
